Combined with the results of Cooperberg, higher MVD counts in pathological tissue could strengthen the use of T1‐3 clinical stage for BCR prediction among patients with PC, which could complement the BCR risk stratification tool in EAU. The gene discussed is BCR; the disease is pachyonychia congenita.